Dexcom (CH:DC4)
NASDAQ:DC4
DC4 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueDexcom’s core business is a durable consumables model: regularly replaced sensors and periodic transmitters create annuity-like demand from an installed base. That structural recurring revenue supports predictable top-line, higher lifetime customer value, and resilience versus one-time device sales.
Sustained Margin ExpansionMaterial margin improvement reflects scalable manufacturing, pricing power, and operating leverage as volumes and efficiencies grow. Higher and expanding gross and operating margins bolster free cash flow potential and fund R&D and commercial investments without diluting returns.
Strong Cash Generation & Balance SheetRobust operating and free cash flow combined with a solid cash buffer and reduced leverage improves financial flexibility. This supports reinvestment, M&A optionality, share repurchases, and weathering reimbursement timing, enhancing long-term strategic optionality and capital allocation.
Bears Say
Reimbursement And Tender DependenceDurable growth depends on broad payer coverage; uncertain CMS timing leaves a large U.S. segment inaccessible for now. International expansion also relies on country tenders, which are lumpy. Both reimbursement and tender dynamics create sustained visibility risk for adoption and revenue.
Input-cost And Ramp Pressure On MarginsExposure to commodity and logistics inputs can structurally compress gross margins if costs persist. Simultaneous investments and Ireland manufacturing ramp will elevate near-term operating spend, testing the durability of recent margin gains unless offset by productivity or pricing.
Market Moderation And CompetitionStructural competition and a potentially moderating U.S. CGM market increase the need to sustain new patient starts and product conversions. Slower organic adoption or stronger competitor moves would pressure revenue growth and require higher sales/marketing or product differentiation to maintain share.
Dexcom News
DC4 FAQ
What was Dexcom’s price range in the past 12 months?
Currently, no data Available
What is Dexcom’s market cap?
Currently, no data Available
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Jul 23, 2026 which is in 32 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Apr 30, 2026. The company reported $0.447 earnings per share for the quarter, beating the consensus estimate of $0.372 by $0.075.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.48.
How many shares outstanding does Dexcom have?
Currently, no data Available
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.447 in its last earnings report, beating expectations of $0.372. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in CH:DC4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.54%
12-Months-Change
Fundamentals
Return on Equity
33.83%
Trailing 12-Months
Asset Growth
-1.75%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.
DC4 Company Deck
DC4 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a largely positive view: strong revenue growth (15% reported, 12% organic), robust margin expansion (gross margin improvement of ~600 bps and large increases in operating income and EBITDA margins), record global new patient starts, solid cash generation (~$2.4B) and successful product and reimbursement catalysts (G7 15-day uptake, Prime Therapeutics coverage, international wins). Key risks and constraints—chiefly CMS timing uncertainty, a potential 50–100 basis point gross margin headwind from fuel/resin costs, reliance on tenders for international growth, and the need to sustain record new patient starts in the U.S.—temper but do not outweigh the positive operational and financial momentum communicated on the call.View all CH:DC4 earnings summariesDC4 Revenue Breakdown
71.53% U.S.
28.47% International
DC4 Stock 12 Month Forecast
Average Price Target
$66.65
Edwards Lifesciences
―
Insulet
―
Smith & Nephew Snats
―
Steris
―
Tandem Diabetes Care
―
Options Prices
Currently, No data available
---